Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
PRNewswire - November 1, 2001
Investors from the Seattle area are invited to attend the presentation at noon (PST), Monday, Nov. 5. This meeting will take place at the Washington Athletic Club, 1325 Sixth Avenue, Seattle, Washington. Those interested in attending should call 650-624-1041 to RSVP.
The Seattle presentation will also be available via conference call and webcast. To listen to the conference call, please dial 877-232-1251 (international: 706-634-5936). A webcast that accompanies the call may be accessed through the "Company Presentations" section on VaxGen's Investor Relations web site at http://www.vaxgen.com/invest/, or through http://www.vcall.com. A replay will be available for 24 hours after the live call by dialing 800-642-1687 (international: 706-645-9291), passcode 2292642. The webcast will be archived for 30 days on http://www.vaxgen.com and http://www.vcall.com.
Drs. Francis and Gordon will also present updates next week in New York and West Palm Beach, Fla. The investment communities from these areas are invited to attend.
The New York meeting will take place at 6:00 p.m. (EST), Tuesday, Nov. 6, 2001, at the Essex House, 160 Central Park South, New York City.
The West Palm Beach meeting will take place at 6:00 p.m. (EST), Wednesday, Nov. 7, 2001, at the Hilton Palm Beach Airport Hotel, 150 Australian Avenue, West Palm Beach, Fla.
To attend any of these meetings in person, please RSVP to Amy Shuba by e- mail at ashuba@vaxgen.com or by phone at 650-624-1041.
VaxGen is the only company with preventive HIV vaccines in Phase III trials, the final stage before regulatory approval can be sought. The company's two Phase III trials -- one in North America and Europe and another in Thailand -- are designed to determine how well the vaccine, AIDSVAX, prevents HIV infection in humans. VaxGen's North American/European trial is scheduled to conclude no later than the end of 2002, with the Thai trial scheduled for conclusion the following year. VaxGen is located in Brisbane, California. For more information, please visit the company's web site at http://www.vaxgen.com.
NOTE: AIDSVAX(R) is a registered trademark of VaxGen.
Note: This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward- looking statements are subject to known and unknown risks, uncertainties or other factors that may cause VaxGen's actual results to be materially different from historical results, expressed or implied by such forward- looking statements. Factors that might cause such a difference include, but are not limited to, uncertainties related to the progress, costs and results of the Company's Phase III clinical trials and the Company's ability to fund the Thai trial to completion, the progress of other internal research and development projects, the Company's ability to demonstrate efficacy of AIDSVAX in clinical trials, the Company's ability to obtain regulatory approval to market AIDSVAX and the Company's ability to secure commercial-scale manufacturing for AIDSVAX. Reference should be made to VaxGen's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 30, 2001, under the headings "Factors Affecting Future Results" and "Business" and to VaxGen's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 14, 2001, under the heading "Risk Factors," for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release or to reflect the occurrence of anticipated events.
011101
PR011101
Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .